DXA assessment and fracture prevention in hormone positive breast cancer patients after treatment initiation with aromatase inhibitors: A registry-based cohort study.
Aromatase inhibitors induced bone loss
Breast cancer
Fracture prevention
Osteoporosis
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
05
2023
revised:
24
07
2023
accepted:
22
08
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Several guidelines have been proposed to prevent aromatase inhibitors induced bone loss (AIBL), but there is scarce data on their endorsement in clinical practice. To assess bone health evaluation and fracture prevention in postmenopausal women with estrogen receptor (ER)-positive breast cancer after aromatase inhibitors (AI) initiation. An historical cohort analysis based on data from the cancer and osteoporosis Maccabi Health Services (MHS) registries from Jan 1st 2009 to Dec 31st 2020. Cases of estrogen receptor (ER)-positive breast cancer were extracted. Index date was set as the first aromatase inhibitors (AI) purchase. Variables such as age, BMI, smoking history, alcohol use, rheumatoid arthritis, diabetes, glucocorticosteroid use, previous fractures, BMD T-scores and purchases of AI and anti-resorptive agents were collected. Age under 50, previous cancer, prior major osteoporotic fractures and prior anti-resorptive treatment were exclusion criteria. Kaplan-Meier curves were generated to assess the time to outcomes. Multivariable Cox's proportional hazards survival model was performed. A total of 8617 women initiating AI were eligible. The median follow up was 6.1 years. The mean (SD) age at index was 62.8 (9.2), the mean (SD) BMI was 29.1 (5.6). The mean (SD) T-score was -1.3 (1.2) at the lumbar spine, -1.5 (0.9) at the femoral neck and -1.0 (1.0) at the total hip. Twenty percent had type 2 diabetes, 8.1 % were active smokers, 3.8% had rheumatoid arthritis and 1.2% were exposed to glucocorticoids.A total of 37% and 53% underwent a DXA scan at 1 and 2 years from AI initiation, and 12% and 17% were prescribed an anti-resorptive agent at 1 and 2 years from index. Advanced age was associated with a higher rate of evaluation and treatment, while obesity and diabetes were associated with a lower rate. The cumulative incidence of a major osteoporotic fracture was 8.8 and 15.8 % at 5 and 10 years, respectively. Despite the excess risk of fractures, bone health assessment and preventive treatment are still partial and postponed in breast cancer AI treated patients. Strategies to ensure appropriate care are needed.
Sections du résumé
Background
UNASSIGNED
Several guidelines have been proposed to prevent aromatase inhibitors induced bone loss (AIBL), but there is scarce data on their endorsement in clinical practice.
Aim
UNASSIGNED
To assess bone health evaluation and fracture prevention in postmenopausal women with estrogen receptor (ER)-positive breast cancer after aromatase inhibitors (AI) initiation.
Methods
UNASSIGNED
An historical cohort analysis based on data from the cancer and osteoporosis Maccabi Health Services (MHS) registries from Jan 1st 2009 to Dec 31st 2020. Cases of estrogen receptor (ER)-positive breast cancer were extracted. Index date was set as the first aromatase inhibitors (AI) purchase. Variables such as age, BMI, smoking history, alcohol use, rheumatoid arthritis, diabetes, glucocorticosteroid use, previous fractures, BMD T-scores and purchases of AI and anti-resorptive agents were collected. Age under 50, previous cancer, prior major osteoporotic fractures and prior anti-resorptive treatment were exclusion criteria. Kaplan-Meier curves were generated to assess the time to outcomes. Multivariable Cox's proportional hazards survival model was performed.
Results
UNASSIGNED
A total of 8617 women initiating AI were eligible. The median follow up was 6.1 years. The mean (SD) age at index was 62.8 (9.2), the mean (SD) BMI was 29.1 (5.6). The mean (SD) T-score was -1.3 (1.2) at the lumbar spine, -1.5 (0.9) at the femoral neck and -1.0 (1.0) at the total hip. Twenty percent had type 2 diabetes, 8.1 % were active smokers, 3.8% had rheumatoid arthritis and 1.2% were exposed to glucocorticoids.A total of 37% and 53% underwent a DXA scan at 1 and 2 years from AI initiation, and 12% and 17% were prescribed an anti-resorptive agent at 1 and 2 years from index. Advanced age was associated with a higher rate of evaluation and treatment, while obesity and diabetes were associated with a lower rate. The cumulative incidence of a major osteoporotic fracture was 8.8 and 15.8 % at 5 and 10 years, respectively.
Conclusions
UNASSIGNED
Despite the excess risk of fractures, bone health assessment and preventive treatment are still partial and postponed in breast cancer AI treated patients. Strategies to ensure appropriate care are needed.
Identifiants
pubmed: 37664159
doi: 10.1016/j.jbo.2023.100501
pii: S2212-1374(23)00034-9
pmc: PMC10474058
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100501Informations de copyright
© 2023 The Authors. Published by Elsevier GmbH.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Osteoporos Int. 2003 Nov;14(11):895-904
pubmed: 12920507
J Clin Oncol. 2010 Jan 20;28(3):509-18
pubmed: 19949017
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Lancet. 2002 Jun 22;359(9324):2131-9
pubmed: 12090977
Clin Breast Cancer. 2006 Jun;7(2):127-32
pubmed: 16800971
N Engl J Med. 1998 Sep 10;339(11):733-8
pubmed: 9731089
J Bone Oncol. 2021 Mar 18;28:100355
pubmed: 33948427
J Bone Oncol. 2017 Mar 23;7:1-12
pubmed: 28413771
Osteoporos Int. 2014 Dec;25(12):2817-24
pubmed: 25092059
Arch Osteoporos. 2020 Feb 26;15(1):27
pubmed: 32103347
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978
J Bone Miner Res. 1998 May;13(5):763-73
pubmed: 9610739
Maturitas. 2017 Jan;95:65-71
pubmed: 27802892
Osteoporos Int. 2003 Jan;14(1):61-8
pubmed: 12577186
J Clin Oncol. 2019 Nov 1;37(31):2916-2946
pubmed: 31532726
Lancet. 2002 May 18;359(9319):1761-7
pubmed: 12049882
Breast Cancer Res. 2014;16(2):206
pubmed: 25032258
Isr Med Assoc J. 2021 Jan;23(1):23-27
pubmed: 33443338
Cancer. 2003 Nov 1;98(9):1802-10
pubmed: 14584060
Breast Cancer Res Treat. 2016 Jan;155(1):151-7
pubmed: 26687384